Stonegate Capital Partners Updates Coverage on NZX Limited (NZSE: NZX) 1H25
NZX reported revenue, operating profit, and EBTIDA of $61.7M, $11.6M, and $24.1M, respectively. This compares to our estimates of $64.1M, $13.6M, and $25.0M. Differences between actuals and our estimates were primarily driven by macro uncertainty. We expect that a portion of this delta will be compensated for in 2H25, as macro uncertainty abates. Download Report […]
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (NASDAQ: CING) 2Q25
Cingulate reported 2Q25 results that highlight continued progress toward the commercial launch of its lead ADHD asset, CTx-1301. The Company remains focused on advancing its Precision Timed Release™ (PTR™) platform, designed to address gaps in current ADHD treatments by enabling true once-daily dosing. With a differentiated product profile and a large U.S. market opportunity, management […]
Stonegate Capital Partners Updates Coverage on Incannex Healthcare Inc. (NasdaqGM:IXHL) 3Q25 – Update
Incannex Healthcare Inc. (NasdaqGM:IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NasdaqGM:IXHL). Recently, IXHL has made significant progress on its IHL-42X asset after very positive topline results from the Phase 2 study have returned, with more granular data trickling in. Both the low and high dose groups achieved a statistically significant reduction […]
Stonegate Capital Partners Updates Coverage On Aemetis Inc. (Nasdaq: AMTX) 2Q25
Aemetis’ results reinforced that the Company’s Dairy RNG platform is entering a high-growth phase, supported by regulatory approvals, capacity expansion, and favorable policy developments. Eleven digesters produced 106,400 MMBtu of RNG in the quarter, generating $3.1M in revenue. In June, CARB approved seven new LCFS pathways at a blended CI score of -384, unlocking ~120% […]
Stonegate Capital Partners Updates Coverage on Burcon Nutrascience Corporation (TSX: BU) 1Q26
During 1Q26, Burcon advanced meaningfully in its commercialization strategy. Within 90 days of commissioning its Galesburg facility, the Company achieved first commercial production of its next-generation Peazazz® C pea protein and debuted FavaPro™ fava protein. Initial shipments of Peazazz® C were completed during the quarter, supported by strong market reception and customer trials. Burcon also […]
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (NASDAQ: ACOG) 2Q25
Alpha Cognition advanced its first full quarter of ZUNVEYL® commercialization in 2Q25, driving meaningful early adoption in the U.S. long-term care (LTC) market and securing a key regulatory milestone in China. By quarter-end, ZUNVEYL (benzgalantamine) had been ordered in over 300 LTC facilities across priority regions, with 65% placing repeat orders, signaling strong clinical confidence […]
Stonegate Capital Partners Updates Coverage On Surf Air Mobility Inc. (NYSE: SRFM) 2Q25
SRFM reported revenue, Adj. EBITDA, and Adj. EPS of $27.4M, ($9.5)M, and ($1.34), respectively, exceeding both revenue and EBITDA guidance for the quarter. This performance reflects a clear inflection point for the Company, driven by improved airline operations, continued optimization of the On Demand segment, and growing momentum in its SurfOS software platform. Notably, airline […]
Stonegate Capital Partners Updates Coverage on Sky Harbour Group Corporation (NYSE: SKYH) 2Q25
Sky Harbour maintained strong operational momentum in 2Q25, underpinned by campus openings, leasing activity, and construction progress across its growing nationwide network. During the quarter, the Company commenced operations at Dallas Addison (ADS) and Seattle Boeing Field (BFI) and prepared for the start of resident flight operations at Denver Centennial (APA) in early 3Q25. Miami […]
Stonegate Capital Partners Updates Coverage on Valens Semiconductor Ltd. (NYSE:VLN) 2Q25
Valens Semiconductor posted 2Q25 revenue of $17.1M, above guidance of $16.5– $16.8M, marking its fifth consecutive quarter of growth and up from $16.8M in 1Q25 and $13.6M in 2Q24. GAAP gross margin was 63.5% (non-GAAP 67.2%), within guidance and up from 62.9% in 1Q25. Adjusted EBITDA loss of $(4.0)M was better than the expected $(4.9)–$(4.4)M […]
Stonegate Capital Partners Updates Coverage On GoHealth Inc. (NASDAQ: GOCO) 2Q25

GoHealth, Inc. delivered a challenged second quarter in 2025, highlighted by revenue declines and contracting margins.